ReviewSeminars in immunopathology2015
The gut microbiota and inflammatory bowel disease.
Review in Seminars in immunopathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 425 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
425 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Evaluation of the association between periodontitis and inflammatory bowel disease: A systematic review and Meta-analysis.BMC gastroenterology · 2025Pooled it
- Evaluation of the Effect of Probiotic Supplementation on Intestinal Barrier Integrity and Epithelial Damage in Colitis Disease: A Systematic Review.Nutrition reviews · 2025Pooled it
- Research trends and hotspots of metabolites and inflammatory bowel disease: a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Efficacy of curcumin supplementation for the treatment and prevention of pouchitis after ileal pouch-anal anastomosis: a randomized controlled trial.European journal of nutrition · 2025Trial
- Adult duck fecal microbiota transplantation alleviates short beak and dwarfism syndrome in ducklings by inhibiting Th17 cell differentiation.Virulence · 2026Article
- Effects of cuproptosis and its application in inflammatory bowel disease (Review).International journal of molecular medicine · 2026Review
- Update on Diet and Nutritional Therapies in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2026Review
- Antibiotic Class-Specific Effects on Inflammatory Bowel Disease: Microbiome Disruption, Risk, and Recovery.International journal of molecular sciences · 2026Review
- FUT2-mediated α1,2-fucosylation in inflammatory bowel disease: mechanisms and translational potential.Molecular biology reports · 2026Review
- Functional Integration of Crosstalk Between Probiotic Lactic Acid Bacteria and Intestinal Immunity Signaling.Probiotics and antimicrobial proteins · 2026Review
- Preventive and therapeutic effects of co-administration of Bacteroides thetaiotaomicron and infliximab on dextran sodium sulfate-induced colitis in mice.Intestinal research · 2026Article
- Association of IBS-associated E. coli strains with epithelial inflammatory responses and tight junction dysregulation in Caco-2 cells.BMC research notes · 2026Article
- Polyclonal antibodies and probiotics improve immune dysfunction in a mouse model of inflammatory bowel disease.Scientific reports · 2026Article
- Discovery of a Colon-Targeted Prodrug As anACS medicinal chemistry letters · 2026Article
- The dual role of lipoteichoic acid: from immune modulation to therapeutic applications in disease treatment.Inflammopharmacology · 2026Review
- Early fecal metabolomic profiling for predicting acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.Scientific reports · 2026Article
- Immunoenhancing Effect of Lactobacillus Kefiranofaciens ZW18 Postbiotic On Cyclophosphamide-induced Immunosuppressed Mice.Probiotics and antimicrobial proteins · 2026Article
- Gut Microbiota Alterations and Dysbiosis Patterns in Pediatric Inflammatory Bowel Disease: Clinical Correlations and Therapeutic Impact.Journal of clinical medicine · 2026Article
- Redrawing the gut map: evolving probiotic approaches to microbiota modulation in inflammatory bowel disease.Antonie van Leeuwenhoek · 2026Review
365 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gut. Although the precise cause of IBD remains unknown, the most accepted hypothesis of IBD pathogenesis to date is that an aberrant immune response against the gut microbiota is triggered by environmental factors in a genetically susceptible host. The advancement of next-generation sequencing technology has enabled identification of various alterations of the gut microbiota composition in IBD. While some results related to dysbiosis in IBD are different between studies owing to variations of sample type, method of investigation, patient profiles, and medication, the most consistent observation in IBD is reduced bacterial diversity, a decrease of Firmicutes, and an increase of Proteobacteria. It has not yet been established how dysbiosis contributes to intestinal inflammation. Many of the known IBD susceptibility genes are associated with recognition and processing of bacteria, which is consistent with a role of the gut microbiota in the pathogenesis of IBD. A number of trials have shown that therapies correcting dysbiosis, including fecal microbiota transplantation and probiotics, are promising in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.